PriceTargets.com logo

Baudax Bio - BXRX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $40.00
  • Forecasted Upside: 6,796.55%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.58 As of 06/8/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for BXRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Baudax Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BXRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BXRX

Analyst Price Target is $40.00
▲ +6,796.55% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Baudax Bio in the last 3 months. The average price target is $40.00, with a high forecast of $40.00 and a low forecast of $40.00. The average price target represents a 6,796.55% upside from the last price of $0.58.

This chart shows the closing price for BXRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in Baudax Bio. This rating has held steady since December 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/3/2023Noble FinancialReiterated RatingOutperform ➝ Market PerformLow
9/6/2022Noble FinancialLower Target$40.00Low
1/4/2022UBS GroupInitiated CoverageOutperformHigh
5/15/2020JMP SecuritiesInitiated CoverageOutperform$260.00High
5/11/2020OppenheimerLower TargetOutperform$320.00 ➝ $280.00Low
2/21/2020Piper SandlerBoost Target$220.00 ➝ $280.00Low
1/21/2020OppenheimerReiterated RatingBuy$240.00High
11/22/2019Janney Montgomery ScottInitiated CoverageBuy$240.00Low
11/22/2019Piper Jaffray CompaniesInitiated CoverageOverweight$240.00Low
(Data available from 6/8/2018 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/10/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/9/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/8/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/10/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/9/2023
  • 5 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2023

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Baudax Bio logo
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Read More

Today's Range

Now: $0.58
Low: $0.54
High: $0.60

50 Day Range

MA: $1.11
Low: $0.52
High: $2.45

52 Week Range

Now: $0.58
Low: $0.50
High: $37.72

Volume

185,441 shs

Average Volume

1,292,189 shs

Market Capitalization

$3.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Baudax Bio?

The following sell-side analysts have issued stock ratings on Baudax Bio in the last twelve months: Noble Financial.
View the latest analyst ratings for BXRX.

What is the current price target for Baudax Bio?

1 Wall Street analysts have set twelve-month price targets for Baudax Bio in the last year. Their average twelve-month price target is $40.00, suggesting a possible upside of 6,796.6%. Noble Financial has the highest price target set, predicting BXRX will reach $40.00 in the next twelve months. Noble Financial has the lowest price target set, forecasting a price of $40.00 for Baudax Bio in the next year.
View the latest price targets for BXRX.

What is the current consensus analyst rating for Baudax Bio?

Baudax Bio currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BXRX, but not buy more shares or sell existing shares.
View the latest ratings for BXRX.

What other companies compete with Baudax Bio?

Other companies that are similar to Baudax Bio include Tivic Health Systems, TRxADE HEALTH, Motus GI, Nuwellis and China Pharma. Learn More about companies similar to Baudax Bio.

How do I contact Baudax Bio's investor relations team?

Baudax Bio's physical mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The company's listed phone number is 484-395-2440 and its investor relations email address is [email protected]. The official website for Baudax Bio is www.baudaxbio.com. Learn More about contacing Baudax Bio investor relations.